SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bunn SK, Bisset WM, Main MJC, et al. Fecal calprotectin: validation as noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 1422.
  • 2
    Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58: 176180.
  • 3
    Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003; 35: 607609.
  • 4
    Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003; 35: 642647.
  • 5
    Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005; 40: 450455.
  • 6
    Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitits than in Crohn's disease. Gut. 2005; 54: 364368.
  • 7
    Bunn SK, Bisset WM, Main MJC, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32: 171177.
  • 8
    Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004; 36: 467470.
  • 9
    Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003; 49: 861867.
  • 10
    Berni Canani R, Tanturri de Horatio L, Terrin G, et al. Combined use of noninvasive test is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006; 42: 915.
  • 11
    Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 1522.
  • 12
    Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterology. 2000; 95: 28312837.
    Direct Link:
  • 13
    Roseth AG, Fagerhol MK, Aadland E, Schionsby H. Assessment of neutrophil dominating protein calprotectin in faeces. A methodology study. Scand J Gastroenterol. 1992; 27: 793798.
  • 14
    Olasfsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002; 91: 4550.
  • 15
    DayDW, JassJR, PriceAB, et al, eds. Inflammatory disorders in the large intestine. In: Morson and Dawson's Gastrointestinal Pathology. Malden, Mass.: Blackwell Publishing; 2003: 472539.
  • 16
    Tsang P, Rotterdam H. Biopsy diagnosis of colitis: possibilities and pitfalls. Am J Surg Pathol. 1999; 23: 423430.
  • 17
    Glickman JN, Bousvaros A, Farraye FA, et al. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol. 2004; 28: 190197.
  • 18
    Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 524533.
  • 19
    Nissen AC, van Gils CE, Menjheere PP, et al. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004; 38: 107108.
  • 20
    Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000; 47: 506513.
  • 21
    Wassell J, Dolwani S, Metzner M, et al. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem. 2004; 41: 230232.
  • 22
    Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008; 103: 162169.
  • 23
    Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008; 14: 3239.
  • 24
    Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008; 14: 4046.
  • 25
    Kokkonen J, Karttunen TJ. Lymphonodular hyperplasia on the mucosa of the lower gastrointestinal tract in children: an indication of enhanced immune response? J Pediatr Gastroenterol Nutr. 2002; 34: 4246.